|
[1]BELLENTANI SF, MARINO M, BEDOGNI G.Epidemiology of non-alcoholic fatty liver disease[J].Dig Dis, 2010, 28 (1) :155-161.
|
|
[2]FAN JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].J Gastroenterol Hepatol, 2013, 28 (1) :11-17.
|
|
[3]YOUNOSSI ZM, STEPANOVA M, RAFIQ N, et al.Pathologic criteria for nonalcoholic steatohepatitis:interprotocol agreement and ability to predict liver-related mortality[J].Hepatology, 2011, 53 (6) :1874-1882.
|
|
[4]ZHANG Q, LI H, XIANG XH, et al.A summary of 2015 academic conference of Tianjin Society of Integrated Traditional Chinese and Western Medicine for Liver Diseases[J].J Clin Hepatol, 2016, 2 (32) :404-405. (in Chinese) 张青, 李海, 向晓辉, 等.天津市中西医结合肝病学会2015年度学术年会会议纪要[J].临床肝胆病杂志, 2016, 32 (2) :404-405.
|
|
[5]ALAM S, MUSTAFA G, ALAM M, et al.Insulin resistance in development and progression of nonalcoholic fatty liver disease[J].World J Gastrointest Pathophysiol, 2016, 7 (2) :211-217.
|
|
[6]YKI-JRVINEN H.Liver fat in the pathogenesis of insulin resistance and type 2 diabetes[J].Dig Dis, 2010, 28 (1) :203-209.
|
|
[7]BREA A, PUZO J.Non-alcoholic fatty liver disease and cardiovascular risk[J].Int J Cardiol, 2013, 167 (4) :1109-1117.
|
|
[8]OKAZAKI S, SHIOI R, NOGUCHI-YACHIDE T, et al.Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptorα/δ (PPARα/δ) dual agonists[J].Bioorg Med Chem, 2016, 24 (21) :5455-5461.
|
|
[9]NEGRESALVAYRE A, AUGE N, AYALA V, et al.Pathological aspects of lipid peroxidation[J].Free Radic Res, 2010, 44 (10) :1125-1171.
|
|
[10]QU LL, YU B, LI Z, et al.Gastrodin ameliorates oxidative stress and proinflammatory response in nonalcoholic fatty liver disease through the AMPK/Nrf2 pathway[J].Phytother Res, 2016, 30 (3) :402-411.
|
|
[11]XU BB, WANG BY.Nonalcoholic fatty liver disease and serum uric acid[J].J Clin Hepatol, 2016, 3 (32) :437-441. (in Chinese) 徐贝贝, 王炳元.非酒精性脂肪性肝病与血清尿酸[J].临床肝胆病杂志, 2016, 3 (32) :437-441.
|
|
[12]NOVO E, BUSLETTA C, BONZO LV, et al.Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells[J].J Hepatol, 2011, 54 (5) :964-974.
|
|
[13]YU J, MARSH S, HU J, et al.The pathogenesis of nonalcoholic fatty liver disease:interplay between diet, gut microbiota, and genetic background[J].Gastroenterol Res Pract, 2016, 2016:2862173.
|
|
[14]COPPLE BL, LI T.Pharmacology of bile acid receptors:evolution of bile acids from simple detergents to complex signaling molecules[J].Pharmacol Res, 2016, 104:9-21.
|
|
[15]SCHAAP FG, TRAUNER M, JANSEN PL.Bile acid receptors as targets for drug development[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (1) :55-67.
|
|
[16]CARR RM, REID AE.FXR agonists as therapeutic agents for non-alcoholic fatty liver disease[J].Curr Atheroscler Rep, 2015, 17 (4) :500.
|
|
[17]MAZUY C, HELLEBOID A, STAELS B, et al.Nuclear bile acid signaling through the farnesoid X receptor[J].Cell Mol Life Sci, 2015, 72 (9) :1631-1650.
|
|
[18]KUMAR DP, ASGHARPOUR A, MIRSHAHI F, et al.Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet alpha cells to promote glucose homeostasis[J].J Biol Chem, 2016, 291 (13) :6626-6640.
|
|
[19]OLIVEIRA MC, GILGLIONI EH, BOER BA, et al.Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiencyrelated postmenopausal obesity and hepatic steatosis in mice[J].Biochim Biophys Acta, 2016, 1862 (11) :2054-2062.
|
|
[20]SATORU K.Choose delicately and reuse adequately:the newly revealed process of autophagy[J].Biol Pharm Bull, 2015, 38 (8) :1098-1103.
|
|
[21]AMIR M, CZAJA MJ.Autophagy in nonalcoholic steatohepatitis[J].Expert Rev Gastroenterol Hepatol, 2011, 5 (2) :159-166.
|
|
[22]MURROW L, DEBNATH J.Autophagy as a stress-response and quality-control mechanism:implications for cell injury and human disease[J].Annu Rev Pathol, 2013, 8:105-137.
|
|
[23]KWANTEN WJ, MARTINET W, MICHIELSEN PP, et al.Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease:a controversial issue[J].World J Gastroenterol, 2014, 20 (23) :7325-7338.
|
|
[24]MUKHOPADHYAY S, PANDA PK, SINHA N, et al.Autophagy and apoptosis:where do they meet?[J]Apoptosis, 2014, 19 (4) :555-566.
|
|
[25]YOULE RJ, NARENDRA DP.Mechanisms of mitophagy[J].Nat Rev Mol Cell Biol, 2011, 12 (1) :9-14.
|
|
[26]ZHENG TY, LI YY, NIE YQ, et al.Impact of intestinal flora on severity of non-alcoholic fatty liver disease[J].J Guangzhou Med Univ, 2016, 44 (1) :9-13. (in Chinese) 郑啼婴, 李瑜元, 聂玉强, 等.肠道菌群对非酒精性脂肪性肝病病变程度的影响[J].广州医科大学学报, 2016, 44 (1) :9-13.
|
|
[27]ZENG QF, YANG GL, WANG CF.Application of probiotics in liver diseases[J].Chin J Immunol, 2016, 32 (11) :1711-1714. (in Chinese) 曾庆丰, 杨桂连, 王春风.益生菌在肝脏疾病方面的应用[J].中国免疫学杂志, 2016, 32 (11) :1711-1714.
|
|
[28]LE ROY T, LLOPIS M, LEPAGE P, et al.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J].Gut, 2013, 62 (12) :1787-1794.
|
|
[29]MUSSO G, CASSADER M, COHNEY S, et al.Emerging liverkidney interactions in nonalcoholic fatty liver disease[J].Trends Mol Med, 2015, 21 (10) :645-662.
|
|
[30]KIRPICH IA, MARSANO LS, MCCLAIN CJ.Gut-liver axis, nutrition, and non-alcoholic fatty liver disease[J].Clin Biochem, 2015, 48 (13-14) :923-930.
|
|
[31]XU R, ZHANG Z, WANG FS.Liver fbrosis:mechanisms of immune-mediated liver injury[J].Cell Mol Immunol, 2012, 4 (9) :296-301.
|
|
[32]TAKEDA N, O'DEA EL, DOEDENS A, et al.Differential activation and antagonistic function of HIF-{alpha}isoforms in macrophages are essential for NO homeostasis[J].Genes Dev, 2010, 24 (5) :491-501.
|
|
[33]IBRAHIM J, NGUYEN AH, REHMAN A, et al.Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver[J].Gastroenterology, 2012, 4 (143) :1061-1072.
|
|
[34]XUAN SY, YUAN C, LU LL, et al.Research advances in susceptibility genes and their role in the pathogenesis of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2016, 32 (3) :446-452. (in Chinese) 宣世英, 袁晨, 芦琳琳, 等.非酒精性脂肪性肝病相关易感基因及其在发病机制中的作用[J].临床肝胆病杂志, 2016, 32 (3) :446-452.
|
|
[35]PINGITORE P, PIRAZZI C, MANCINA RM, et al.Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function[J].Biochim Biophys Acta, 2014, 1841 (4) :574-580.
|
|
[36]HE S, MCPHAUL C, LI JZ, et al.A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis[J].J Biol Chem, 2010, 285 (9) :6706-6715.
|
|
[37]ROMEO S, KOZLITINA J, XING C, et al.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet, 2008, 40 (2) :1461-1465.
|
|
[38]SOOKOIAN S, PIROLA CJ.Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease[J].Hepatology, 2011, 53 (6) :1883-1894.
|
|
[39]LIU YL, REEVES HL, BURT AD, et al.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease[J].Nat Commun, 2014, 5 (4) :4309.
|
|
[40]KOZLITINA J, SMAGRIS E, STENDER S, et al.Exomewide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet, 2014, 46 (4) :352-356.
|
|
[41]SENATES E, YILMAZ Y, COLAK Y, et al.Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease[J].Metab Syndr Relat Disord, 2011, 9 (4) :287-290.
|
|
[42]JIA L, WANG TC, LI Q.Iron overload and study on the relationship between the pathogenesis of nonalcoholic fatty liver disease[J].Chin J PHM, 2015, 31 (2) :193-194. (in Chinese) 贾丽, 王天初, 李权.铁超载与非酒精性脂肪肝发病关系研究近况[J].中国公共卫生管理, 2015, 31 (2) :193-194.
|
|
[43]FENG HP, REN YL.Signiifcance of serum ferritin in patients with non-alcoholic fatty liver disease[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (2) :113-115. (in Chinese) 冯红萍, 任艳玲.非酒精性脂肪性肝病患者血清铁蛋白检测的意义[J/CD].中国肝脏病杂志:电子版, 2016, 8 (2) :113-115.
|
|
[44]CAO W, ZHAO CY.Mitochondrial dysfunction and nonalcoholic fatty liver disease[J].Chin Hepatol, 2011, 16 (3) :256-259. (in Chinese) 曹伟, 赵彩彦.线粒体功能不全与非酒精性脂肪性肝病[J].肝脏, 2011, 16 (3) :256-259.
|
|
[45]GUPTA D, RADHAKRISHNAN M, KURHE Y.Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice[J].Steroids, 2015, 96 (11) :95-102.
|
DownLoad: